U.S. fraud charges pummel Indivior shares

Indivior fell 75.90p (72%) to 30.05p on Wednesday after the U.S. Department of Justice indicted the company for allegedly defrauding providers and payers to increase prescriptions of its opioid dependence drug Suboxone sublingual film. Wednesday's move translates to a market cap loss of £551.9 million ($721.9 million).

Indivior plc (LSE:INDV) is charged with conspiracy, wire fraud, mail fraud and healthcare fraud. If convicted, the company would need to pay at least $3 billion for illegally obtained revenues and forfeit all of its assets, inventory and property, including 11 patents related to Suboxone buprenorphine/naloxone sublingual film...